Loading…

READY TO ROCK?

Click the button below to start exploring our website and learn more about our awesome company
Start exploring

Onconova Therapeutics (NASDAQ: ONTX) Reduced to Hold at Zacks Investment Research

Onconova (NASDAQ: ONTX) was downgraded by Zacks.com  from a “acquire” ranking to a “hold” score in a research note released to capitalists on Thursday, Zacks.com reports.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical business. It concentrates on discovering and creating little molecule medicine candidates to deal with cancer cells. The Company‘s products under various stages of development consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 as well as Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

A number of various other equities research analysts likewise lately talked about the company. Noble Financial reissued a “get” score as well as issued a $11.00 cost purpose on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their cost target on Onconova Therapeutics from $29.00 to $12.00 and also set a “get” rating on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened up at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and also a twelve month high of $28.95. The business has a 50 day relocating average rate of $2.90 as well as a two-hundred day relocating typical cost of $4.16. The company has a market cap of $46.76 million, a P/E proportion of -1.82 and also a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly incomes outcomes on Thursday, November 11th. The biopharmaceutical business reported ($ 0.22) incomes per share for the quarter, topping analysts’ consensus estimates of ($ 0.33) by $0.11. Onconova Therapeutics had an adverse return on equity of 59.78% and an adverse net margin of 8,294.27%. The firm had earnings of $0.06 million throughout the quarter, compared to the agreement price quote of $0.06 million. During the same quarter in the previous year, the firm uploaded ($ 0.45) EPS. As a group, research analysts anticipate that Onconova Therapeutics will certainly publish -1.18 EPS for the existing year.

A variety of hedge funds have lately bought and sold shares of ONTX. GSA Capital Partners LLP purchased a new setting in Onconova Therapeutics throughout the third quarter worth $922,000. Hudson Bay Resources Monitoring LP bought a brand-new setting in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC got a new placement in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC bought a brand-new position in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Lastly, Dimensional Fund Advisors LP purchased a brand-new position in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds and also various other institutional financiers own 13.36% of the business’s stock.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company, which participates in the identification and growth of oncology therapeutics. It concentrates on finding and developing tiny particle medication candidates to deal with cancer. The company was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA

. Get a free duplicate of the Zacks research report on Onconova Therapeutics (ONTX).

To find out more concerning research offerings from Zacks Investment Research, check out Zacks.com.

This immediate news alert was created by narrative scientific research innovation as well as monetary information from Market in order to provide readers with the fastest and most accurate reporting. This story was examined by Market’s editorial group before publication. 

 

SHOULD YOU INVEST $1,000 IN ONCONOVA THERAPEUTICS TODAY?

Prior to you consider Onconova Therapeutics, you’ll want to hear this.

Market keeps track of Wall Street’s top-rated and best executing research experts and the stocks they recommend to their clients each day. Market has actually determined the five stocks that top analysts are silently murmuring to their clients to acquire currently prior to the broader market catches on … and Onconova Therapeutics had not been on the listing.

While Onconova Therapeutics currently has a “Buy” score among analysts, top-rated analysts believe these 5 stocks are much better acquires.